Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China flag China · Delayed Price · Currency is CNY
16.13
+0.07 (0.44%)
Apr 30, 2026, 11:29 AM CST
-35.76%
Market Cap 2.68B
Revenue (ttm) 418.18M
Net Income (ttm) 55.16M
Shares Out 166.80M
EPS (ttm) 0.33
PE Ratio 48.72
Forward PE n/a
Dividend 0.20 (1.27%)
Ex-Dividend Date Jul 10, 2025
Volume 2,460,803
Average Volume 3,815,648
Open 16.04
Previous Close 16.06
Day's Range 15.99 - 16.41
52-Week Range 14.46 - 31.13
Beta 0.53
RSI 37.22
Earnings Date Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 574
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688089
Full Company Profile

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 563.14 million, an increase of 1.36% compared to the previous year's 555.59 million. Earnings were 143.72 million, an increase of 15.71%.

Financial Statements

News

There is no news available yet.